Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Ptc Therapeutics, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

During the period ended June 30, 2026, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading “Quantitative and Qualitative Disclosures about Market Risk” in our 2025 Annual Report. 54 Table of Contents